Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Celgene Int'l.: CHMP Adopts Positive Opinion For REVLIMID - Quick Facts

RELATED NEWS
Trade CELG now with 

Celgene International Sàrl (CELG: Quote) said the European Medicines Agency's or EMA: Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion for REVLIMID to treat patients with transfusion-dependent anemia due to low or intermediate-1-risk myelodysplastic syndromes or MDS associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.

The CHMP, that reviews applications for all 27 member states in the European Union or EU, as well as Norway and Iceland, has recommended approval for REVLIMID in this indication. The European Commission, which generally follows the recommendation of the CHMP, is believed to make its final decision within two to three months.

MDS is a type of cancer where the production of blood cells and platelets by the bone marrow is disrupted, which can often lead to severe anemia, infections and bleeding.

The CHMP positive opinion was based on the results of MDS-004, a phase III, multi-center, randomized, double-blind, placebo-controlled trial. The largest trial of MDS del(5q) patients conducted to-date, MDS-004 compared the efficacy and safety of once-daily oral treatment with REVLIMID to placebo in 205 patients at 37 participating centers throughout Europe.

Register
To receive FREE breaking news email alerts for Celgene Corporation and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Eurozone's consumer confidence improved unexpectedly in October after weakening in the previous four months, preliminary data from the European Commission showed Thursday. The flash consumer confidence indicator rose to -11.1 from a seven-month low of -11.4 in September. Economists had forecast a... After reporting first-time claims for U.S. unemployment benefits at a fourteen-year low in the previous week, the Labor Department released a report on Thursday showing that initial jobless claims rebounded in the week ended October 18th. After turning lower over the course of the previous session, stocks are likely to move back to the upside in early trading on Thursday. The major index futures are currently pointing to a sharply higher open for the markets, with the Dow futures up by 136 points.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.